Literature DB >> 31920003

Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.

Daniel W Kneller1, Johnson Agniswamy1, Robert W Harrison2, Irene T Weber1,3.   

Abstract

Drug-resistance is a serious problem for treatment of the HIV/AIDS pandemic. Potent clinical inhibitors of HIV-1 protease show several orders of magnitude worse inhibition of highly drug-resistant variants. Hence, the structure and enzyme activities were analyzed for HIV protease mutant HIV-1 protease (EC 3.4.23.16) (PR) with 22 mutations (PRS5B) from a clinical isolate that was selected by machine learning to represent high-level drug-resistance. PRS5B has 22 mutations including only one (I84V) in the inhibitor binding site; however, clinical inhibitors had poor inhibition of PRS5B activity with kinetic inhibition value (Ki ) values of 4-1000 nm or 18- to 8000-fold worse than for wild-type PR. High-resolution crystal structures of PRS5B complexes with the best inhibitors, amprenavir (APV) and darunavir (DRV) (Ki ~ 4 nm), revealed only minor changes in protease-inhibitor interactions. Instead, two distinct clusters of mutations in distal regions induce coordinated conformational changes that decrease favorable internal interactions across the entire protein subunit. The largest structural rearrangements are described and compared to other characterized resistant mutants. In the protease hinge region, the N83D mutation eliminates a hydrogen bond connecting the hinge and core of the protease and increases disorder compared to highly resistant mutants PR with 17 mutations and PR with 20 mutations with similar hinge mutations. In a distal β-sheet, mutations G73T and A71V coordinate with accessory mutations to bring about shifts that propagate throughout the subunit. Molecular dynamics simulations of ligand-free dimers show differences consistent with loss of interactions in mutant compared to wild-type PR. Clusters of mutations exhibit both coordinated and antagonistic effects, suggesting PRS5B may represent an intermediate stage in the evolution of more highly resistant variants. DATABASES: Structural data are available in Protein Data Bank under the accession codes 6P9A and 6P9B for PRS5B/DRV and PRS5B/APV, respectively.
© 2020 Federation of European Biochemical Societies.

Entities:  

Keywords:  AIDS; HIV; HIV protease; X-ray crystallography; drug-resistance; evolution of resistance

Mesh:

Substances:

Year:  2020        PMID: 31920003      PMCID: PMC7343616          DOI: 10.1111/febs.15207

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  76 in total

1.  Mutations in HIV-1 gag and pol compensate for the loss of viral fitness caused by a highly mutated protease.

Authors:  Milan Kozísek; Sandra Henke; Klára Grantz Sasková; Graeme Brendon Jacobs; Anita Schuch; Bernd Buchholz; Viktor Müller; Hans-Georg Kräusslich; Pavlína Rezácová; Jan Konvalinka; Jochen Bodem
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

3.  Conformational variation of an extreme drug resistant mutant of HIV protease.

Authors:  Chen-Hsiang Shen; Yu-Chung Chang; Johnson Agniswamy; Robert W Harrison; Irene T Weber
Journal:  J Mol Graph Model       Date:  2015-09-08       Impact factor: 2.518

4.  Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.

Authors:  Mina Henes; Klajdi Kosovrasti; Gordon J Lockbaum; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer; Troy W Whitfield
Journal:  Biochemistry       Date:  2019-08-19       Impact factor: 3.162

5.  Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.

Authors:  John M Louis; József Tözsér; Julien Roche; Krisztina Matúz; Annie Aniana; Jane M Sayer
Journal:  Biochemistry       Date:  2013-10-15       Impact factor: 3.162

6.  Extreme multidrug resistant HIV-1 protease with 20 mutations is resistant to novel protease inhibitors with P1'-pyrrolidinone or P2-tris-tetrahydrofuran.

Authors:  Johnson Agniswamy; Chen-Hsiang Shen; Yuan-Fang Wang; Arun K Ghosh; Kalapala Venkateswara Rao; Chun-Xiao Xu; Jane M Sayer; John M Louis; Irene T Weber
Journal:  J Med Chem       Date:  2013-05-01       Impact factor: 7.446

7.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Azhar K Hussain; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

8.  Elucidating a relationship between conformational sampling and drug resistance in HIV-1 protease.

Authors:  Ian Mitchelle S de Vera; Adam N Smith; Maria Cristina A Dancel; Xi Huang; Ben M Dunn; Gail E Fanucci
Journal:  Biochemistry       Date:  2013-05-01       Impact factor: 3.162

9.  Prediction of HIV drug resistance from genotype with encoded three-dimensional protein structure.

Authors:  Xiaxia Yu; Irene T Weber; Robert W Harrison
Journal:  BMC Genomics       Date:  2014-07-14       Impact factor: 3.969

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  3 in total

Review 1.  HIV Protease: Historical Perspective and Current Research.

Authors:  Irene T Weber; Yuan-Fang Wang; Robert W Harrison
Journal:  Viruses       Date:  2021-05-06       Impact factor: 5.048

2.  Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

Authors:  Simeon Eche; Ajit Kumar; Nelson Sonela; Michelle L Gordon
Journal:  Biomolecules       Date:  2021-03-24

3.  Single-Agent and Fixed-Dose Combination HIV-1 Protease Inhibitor Drugs in Fission Yeast (Schizosaccharomyces pombe).

Authors:  Jiantao Zhang; Kasey Vernon; Qi Li; Zsigmond Benko; Anthony Amoroso; Mohamed Nasr; Richard Y Zhao
Journal:  Pathogens       Date:  2021-06-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.